Lantheus Q3 net income falls 19% to $22.4 million

Bitget2026/11/05 12:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lantheus’ third-quarter 2026 GAAP diluted earnings fell 20% to $0.33 per share, while revenue rose to $389.9 million.
Neuraceq revenue more than doubled to $45.6 million, while PYLARIFY revenue declined to $238.9 million.
The FDA granted approval for Alzheimer’s imaging agent TAUKLARIFY and final approval for neuroendocrine tumor treatment BRAVNETSA.
The pending Curium merger offers $102.50 per share in cash and contingent value rights worth up to $12 per share.
Full-year 2026 financial guidance was suspended in connection with the pending transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870782) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lantheus Q3 net income falls 19% to $22.4 million

You may also like

Crypto prices